The associations between drug use, indicators of nutritional status and vitamin d levels, a cross-sectional analysis of a polypharmaceutical geriatric outpatient population

Vitamin D Levels ◽

Incidence And Mortality ◽

ABSTRACTA potential protective role of vitamin D serum levels on overall adverse outcomes of SARS-CoV-2 infection or COVID-19 on populations had been suggested previously based upon single-point cross-sectional analysis of 8 April 2020 data from 20 European countries assuming comparable underlying confounding variables for these populations, at an early stage of the current pandemic. Comparative time-series cross-sectional analysis of the COVID-19 data from 12 March (early pre-peak) to 26 July (late post-peak of infections) 2020 was performed to assess the strength of the assertion. The study subjects included 1,829,634 COVID-19 cases (11.11% of total worldwide) and 179,135 associated deaths (27.45 % of total worldwide) on 26 July 2012. Previously suggested cross-sectional study design and methodology could not consistently and significantly (p-value≥0.05) support the notion of the potential protective role of the mean serum vitamin D levels of the populations on COVID-19 incidence and mortality. However, the exponential correlative model, as well as alternative simple regression analysis on ln and Log10 transformed COVID-19 data for the time period indicated improved consistently negative covariation with vitamin D levels. Additionally, the later methodology increased the predictive potential for explaining the variability in data [R2 by 1.27-1.96 fold, adjusted-R2 by 1.33-2.47, p-value=0.0457-0.0035, for cases/million; R2 by 1.81-2.67, adjusted-R2 by 2.21-3.74 fold for deaths/million, p-value=0.0049-0.0228). Considering, the established role of vitamin D in immune system functioning randomized well-controlled trials may be suggested to evaluate/assess the potential protective role of vitamin D in reducing the COVID-19 impact on populations.

Prognosis in metastatic lung cancer: vitamin D deficiency and depression—a cross-sectional analysis

BMJ Supportive & Palliative Care ◽

10.1136/bmjspcare-2020-002457 ◽

2020 ◽

pp. bmjspcare-2020-002457

Author(s):

Daniel C McFarland ◽

Madalyn Fernbach ◽

William S Breitbart ◽

Christian Nelson

Keyword(s):

Lung Cancer ◽

Vitamin D ◽

Vitamin D Deficiency ◽

Depression Scale ◽

Metastatic Lung Cancer ◽

Cross Sectional ◽

Vitamin D Levels ◽

Metastatic Lung ◽

BackgroundDepression and vitamin D deficiency are common in patients with lung cancer and have prognostic implications in cancer settings. However, their relationship and concomitant survival implications have not been evaluated in patients with metastatic lung cancer specifically. We hypothesised that vitamin D deficiency would be associated with depression and inferior cancer-related survival in patients receiving therapies for stage IV lung cancer.MethodsThis was a cross-sectional analysis of vitamin D, depression and lung cancer characteristics. Vitamin D levels were stratified by level (no deficiency ≥30 units, mild deficiency 20 to 29 units and moderate-to-severe <20 units). Depression was measured by the Hospital Anxiety and Depression Scale-Depression (HADS-D). Survival estimations were made using Cox proportional hazard model and Kaplan-Meier analyses.ResultsVitamin D deficiency was evident in almost half of the sample (n=98) and was associated with significant depression (HADS-D ≥8) (χ2=4.35, p<0.001) even when controlling for age, sex and inflammation (β=-0.21, p=0.03). Vitamin D deficiency and depression were associated with worse survival and showed evidence of an interaction effect (HR 1.5, p=0.04).ConclusionVitamin D deficiency is associated with depression in patients with metastatic lung cancer. Depression modulates the survival implications of vitamin D deficiency in this population. The role of vitamin D deficiency in cancer-related depression warrants further investigation since both are amenable to treatment. Psychological and nutritional prognostic considerations may help inform treatment paradigms that enhance quality of life and survival.

Greater Adherence to Cancer Prevention Guidelines Is Associated with Higher Circulating Concentrations of Vitamin D Metabolites in a Cross-Sectional Analysis of Pooled Participants from 2 Chemoprevention Trials

Journal of Nutrition ◽

10.3945/jn.116.243352 ◽

2017 ◽

pp. jn243352 ◽

Cited By ~ 1

Author(s):

Lindsay N Kohler ◽

Elizabeth A Hibler ◽

Robin B Harris ◽

Eyal Oren ◽

Denise J Roe ◽

...

Keyword(s):

Vitamin D ◽

Cancer Prevention ◽

Vitamin D Metabolites ◽

Cross Sectional ◽

Prevention Guidelines ◽

Association between vitamin D deficiency and exercise capacity in patients with CKD, a cross-sectional analysis

10.1101/2020.10.26.350546 ◽

2020 ◽

Author(s):

Emma L Watson ◽

Thomas J Wilkinson ◽

Tom F O’Sullivan ◽

Luke A Baker ◽

Douglas W Gould ◽

...

Keyword(s):

Skeletal Muscle ◽

Vitamin D ◽

Vitamin D Deficiency ◽

Exercise Capacity ◽

Muscle Mass ◽

Ex Vivo ◽

Muscle Size ◽

Cross Sectional ◽

AbstractEvidence is growing for a role of vitamin D in regulating skeletal muscle mass, strength and functional capacity. Given the role the kidneys play in activating total vitamin D, and the high prevalence of vitamin D deficiency in Chronic Kidney Disease (CKD), it is possible that deficiency contributes to the low levels of physical function and muscle mass in these patients. This is a secondary cross-sectional analysis of previously published interventional study, with ex vivo follow up work. 34 CKD patients at stages G3b-5 (eGFR 25.5 ± 8.3ml/min/1.73m2; age 61 ± 12 years) were recruited, with a sub-group (n=20) also donating a muscle biopsy. Vitamin D and associated metabolites were analysed in plasma by liquid chromatography tandem-mass spectroscopy and correlated to a range of physiological tests of muscle size, function, exercise capacity and body composition. The effects of 1α,25(OH)2D3 supplementation on myogenesis and myotube size was investigated in primary skeletal muscle cells from vitamin D deficient donors. In vivo, there was no association between total or active vitamin D and muscle size or strength, but a significant correlation with was seen with the total form. Ex vivo, 1α,25(OH)2D3 supplementation reduced IL-6 mRNA expression, but had no effect upon proliferation, differentiation or myotube diameter. This early preliminary work suggests that vitamin D deficiency is not a prominent factor driving the loss of muscle mass in CKD, but may play a role in reduced exercise capacity.